Vysis prenatal genetic test gains FDA clearance; IPO proceeds to expand marketing efforts.
This article was originally published in The Gray Sheet
Executive SummaryVYSIS MARKETING OF ANEUVYSION PRENATAL GENETIC TEST should get a boost from the firm's 3.5 mil. share initial public offering. A portion of the proceeds from the proposed IPO, which is expected to bring in about $44.8 mil., is tabbed for expansion of direct sales and marketing capabilities. Downers Grove, Illinois-based Vysis announced 510(k) clearance of the Aneuvysion assay on Oct. 28; the premarket application was submitted to FDA in June.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.